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Background: In the era of targeted agents, combined chemoradio-
therapy remains standard of care for non-resectable stage III non-small 
cell lung cancer (NSCLC). While recognizing that we have probably 
reached a plateau in terms of treatment results using this strategy, it is 
still imperative to reduce toxicities while not compromising efﬁcacy. 
This study aims to evaluate a non-platinum-containing regimen used in 
conjunction with radiotherapy.
Methods: Patients with histologically proven, non-resectable stage 
III NSCLC are eligible for the study. They must be above 18 years 
old, have good performance status, and have adequate bone marrow, 
renal and hepatic function. Patients will receive 2 cycles of induction 
vinorelbine (25mg/m2) and gemcitabine (1000mg/m2) given on days 1 
and 8 every 21 days, followed by radiotherapy 60-66Gy with concur-
rent weekly vinorelbine (15mg/m2). The primary objective is to assess 
the response rate to this regimen and secondary objectives to assess 
tolerability and toxicity.
Results: We have completed the target accrual of 42 patients. There 
are 31 males and 11 females. The median age is 65, range of 41 to 
79. Sixty-one percent has stage IIIB disease and 38.9% has stage IIIA 
disease. Forty-four percent of the patients have adenocarcinoma and 
25% of patients have squamous cell carcinoma. Fifteen patients (36%) 
achieved a partial response after induction chemotherapy. After chemo-
radiotherapy, 7 patients had complete response and 19 patients had 
partial response, giving an overall response rate of 62%. Toxicity data 
is available for 36 patients. Nine patients(25%) had grade 3 or 4 neutro-
penia, 4 patients(11%) had grade 3 esophagitis and 3 patients(8%) had 
grade 3 fatigue.
Conclusion: The toxicities of this regimen are low and the response 
rate is comparable to similar treatment schedules with platinum-based 
chemotherapy.
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Background: concurrent chemoradiotherapy treatment is standard of 
care for patients with stage III NSCLC and a good performance status. 
Optimal chemotherapy have yet to be deﬁned and the role of surgery is 
still unclear.
This prospective study analysed the feasibility and efﬁcacy of weekly 
docetaxel/cisplatin (DC) and concurrent involved-ﬁeld thoracic radio-
therapy (CRT) followed by surgery in good performance status patients 
with stage IIIA/B NSCLC. Primary endpoint is radiological response 
of DC and CRT. Secondary endpoints included toxicity, efﬁcacy of 
surgery, postoperative morbidity and mortality, time to progression and 
overall survival.
Methods: DC consisted of IV docetaxel 20 mg/m2 and cisplatin 20mg/
m2 at days 1,8,15,22,29 and 36. CRT was given in once-daily fractions 
of 1.8 Gy, 5 fractions a week to a total dose of 45 Gy during days 8 to 
36. CT-based planning was used to minimise radiation to the contra 
lateral lung. Invasive and non-invasive investigations were performed 
after induction treatment in order to restage the mediastinum. when me-
diastinal down staging was achieved, surgery was performed in order to 
achieve radical resection. 
Results: Between January 2005 until August 2006, 45 patients were 
included, of whom 43 patients were evaluable. Stage IIIB disease was 
present in 18 patients (cT4N2=10, cT4N0/N1=5 and cN3=3) and 25 had 
stage IIIA-N2 disease. A radiological response was seen in 20 patients 
(47%) and 8 (19%) showed progressive disease. Toxicity was mild.
Explorative thoracotomy was performed in 25 (58%) patients. Of 
these, 15 were initially staged as IIIA and ten as stage IIIB. Twenty-one 
patients (49%) underwent a radical resection without residual medias-
tinal malignant disease, and ten pneumonectomies (8 left sided) were 
performed. Four patients showed complete pathological response. The 
30 days mortality after operation was 4% (one patient) due to ARDS. 
The median follow up time was 9.9 months. Seventeen patients of 43 
showed progression (40%), of which 13 patients developed distant 
metastases (30%).
Conclusion: Weekly DC and involved-ﬁeld CRT is possible in stage 
III NSCLC, with limited toxicity and nearly half of the treated patients 
(47%) could undergo a radical surgical resection (R0) without residual 
mediastinal malignant disease. Due to low dose chemotherapy almost 
40% of the whole group showed progression of which 30% developed 
distant metastases.
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Background: The therapeutic effects of anticancer drugs on large cell 
neuroendocrine carcinoma (LCNEC), which is classiﬁed as small cell 
lung cancer under the WHO classiﬁcation, have not been established, 
and no consensus on postoperative adjuvant chemotherapy for it has 
been reached. However, last year, a platinum-based regimen with etop-
side for small cell lung cancer, as postoperative adjuvant chemotherapy 
for LCNEC, was reported to signiﬁcantly improve the prognosis, 
requiring follow-up studies.
